WAVRE, Belgium — 28 June 2016: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the appointment of Martin Wax, M.D. and Marc Nolet de Brauwere to the Board of Directors. Dr Martin Wax is a scientific expert in glaucoma with over 30 years of experience in industry and academia. He is currently the Chief Medical Officer and Executive Vice‐President of R&D at PanOptica, Inc., and was formerly Vice‐President and Head of Discovery Research and Pre‐Clinical Sciences at Alcon Laboratories.
Marc Nolet de Brauwere has over 30 years of industry experience and a successful track record in building and leading companies in ophthalmology. He is currently on numerous private and public company boards and serves as CEO of PhysIOL, an innovative med‐tech company active in the conception, manufacturing and sales of cutting‐edge intraocular lenses (IOLs).
Commenting on the appointments,
iSTAR Medical is currently focused on the development of its lead product, MINIject, a device designed to significantly reduce intra‐ocular pressure (IOP) by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is swift and predictable using an injecting mechanism in a single‐step procedure. The company is set to take MINIject to its first human clinical trial later this year.
Dr Martin Wax is currently the Chief Medical Officer and Executive Vice‐President of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories from 2003‐2008. Dr Wax was responsible for the creation and development of the Alcon pharmaceutical portfolio of compounds for the therapeutic areas of glaucoma, retina, allergy, dry eye and anti‐infectives. He is also Clinical Professor of Ophthalmology and Visual Sciences at Rutgers Medical School in Newark, N.J. and has been selected as one of the “Best Doctors in America” 2005‐2008 by his peers. He currently serves as the Chairman of the Board of Directors for Mimetogen, a biotechnology company based in Montreal, Canada, which recently licensed MIM‐D3 to Allergan for the treatment of dry eye disease. Dr Wax has co‐authored more than 200 publications and is a member of a number of renowned Ophthalmological Associations.
Marc Nolet de Brauwere was appointed CEO of PhysIOL in 1997 when he took over the company. He previously held different positions at Petrofina S.A. in the US and as an associate at McKinsey. He is currently an Independent Director at Bone Therapeutics, Cardiatis, Mymicroinvest, Endo Tools Therapeutics, Biotech Coaching and Aliaxis and is currently a Member of the Ashoka Support Network. He holds a Master’s degree in Civil Mining Engineering from the Université Catholique de Louvain, Belgium and a Master’s degree in Industrial Management from the Katholieke Universiteit Leuven.